TITLE

Overhauling clinical trials

AUTHOR(S)
Scott, Christopher Thomas; Baker, Monya
PUB. DATE
March 2007
SOURCE
Nature Biotechnology;Mar2007, Vol. 25 Issue 3, p287
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article examines the designs of clinical trials that adapt midstream which are billed as a cure for challenges in drug development. Drug companies do not apply adaptive designs to individual projects but spread them across their portfolios. The United States Food and Drug Administration helped streamline the drug trials with a focus on adaptive designs.
ACCESSION #
24279320

 

Related Articles

  • Changes needed in clinical trial technology.  // Pharmaceutical Technology Europe;Apr2006, Vol. 18 Issue 4, p16 

    The article reports on findings of Frost and Sullivan's study which showed that revenues in the eClinical Trials (eCT) markets are expected to reach $357.4 million in 2011. The study showed that technology has become an integral part in the drug discovery industry. The study points out that to...

  • The future of drug development: advancing clinical trial design. Orloff, John; Douglas, Frank; Pinheiro, Jose; Levinson, Susan; Branson, Michael; Chaturvedi, Pravin; Ette, Ene; Gallo, Paul; Hirsch, Gigi; Mehta, Cyrus; Patel, Nitin; Sabir, Sameer; Springs, Stacy; Stanski, Donald; Evers, Matthias R.; Fleming, Edd; Singh, Navjot; Tramontin, Tony; Golub, Howard // Nature Reviews Drug Discovery;Dec2009, Vol. 8 Issue 12, p949 

    Declining pharmaceutical industry productivity is well recognized by drug developers, regulatory authorities and patient groups. A key part of the problem is that clinical studies are increasingly expensive, driven by the rising costs of conducting Phase II and III trials. It is therefore...

  • Caution When Traveling Full Speed Ahead. Kaylynn Chiarello-Ebner // Pharmaceutical Technology;Jan2007, Vol. 31 Issue 1, p16 

    The author reflects on the implications of accelerated drug trials among pharmaceutical companies. She focuses on the disadvantage of the process wherein due to the being on fast track there is less time to scale up and fine tune the product, which is a key factor in drug development. She also...

  • Clinical Trial Simulation: A Review. Holford, N.; Ma, S. C.; Ploeger, B. A. // Clinical Pharmacology & Therapeutics;Aug2010, Vol. 88 Issue 2, p166 

    Modeling and simulation in general, and specifically clinical trial simulation (CTS), have been recognized by the (larger) pharmaceutical companies and regulatory authorities as being pivotal to improving the efficiency of the drug development process. This includes the use of CTS to learn about...

  • Clinical Modeling Hits Prime Time. Shaw, Gina // Drug Discovery & Development;Mar2006, Vol. 9 Issue 3, p27 

    The article discusses the use of computer-based modeling and simulation tools and techniques for drug development. According to the article, the methods can replace costly and complicated elements of the drug development process, such as certain aspects of clinical trials. It points out several...

  • Single-Supplier Sourcing in Clinical Trials. Maria, Vincent Santa // Pharmaceutical Processing;Dec2008, Vol. 23 Issue 12, p8 

    The article examines the single-supplier and multiple sourcing in clinical trials. Engaging in multiple clinical trials materials providers for segment-specific clinical trial operations complicates the drug development process. Opting to use a single clinical trial supplies provider simplifies...

  • Esoterix Clinical Trials Services.  // Applied Clinical Trials;Dec2010, Vol. 19 Issue 12, p102 

    The article presents the corporate profile of Esoterix Clinical Trials Services, a company which offers laboratory services and global capabilities to assist drug development and pharmaceutical companies and based in Cranford, New Jersey. The company supports centralized testing and complete...

  • Cephalon/Lundbeck: Parkinson's protection remains a distant dream.  // PharmaWatch: Biotechnology;Jun2005, Vol. 4 Issue 6, p6 

    The article reports on the decision of Cephalon Inc. and Lundbeck Pharmaceuticals to discontinue the development of CEP-1347 for the treatment of Parkinson's disease after a review of the interim results showed that the patient's benefits based on the trial is far-fetched. CEP-1347 is the first...

  • Approval Rating. Lowe, Derek B. // Contract Pharma;Mar2012, Vol. 14 Issue 2, p28 

    The article highlights the importance of symbiosis in the pharmaceutical industry in the U.S. It mentions the complicated issues regarding the finances of clinical trials and drug development processes. It further mentions the need for investors to be more than willing to go along in drug...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics